What makes me nervous is how much is now riding on the covid drug (now that hep B is on slower track and no one really seems to care about the RSV drug or NASH any more) Personally I am long, but not w a huge position as I view ENTA now as a higher risk/reward stock based on covid (although having the HCV revenue stream remains a nice buffer and floor on the stock price) My largest position among small bios right now is MYOV FWIW - I think the endometriosis opportunity is underappreciated - it should do much better than Orlissa
Market Data 
Markets 
AI
